These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32521866)

  • 21. Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN).
    Lecointre L; Velten M; Lodi M; Saadeh R; Lavoué V; Ouldamer L; Bendifallah S; Koskas M; Bolze PA; Collinet P; Canlorbe G; Touboul C; Huchon C; Coutant C; Faller E; Boisramé T; Gantzer J; Martin D; Baldauf JJ; Akladios C; Ballester M
    Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():64-72. PubMed ID: 31864157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
    Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
    Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy.
    Nantasupha C; Muangmool T; Charoenkwan K
    Asian Pac J Cancer Prev; 2022 Nov; 23(11):3791-3799. PubMed ID: 36444592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
    Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY
    J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
    Chung YS; Kim YJ; Lee I; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    PLoS One; 2017; 12(9):e0183754. PubMed ID: 28873393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Chemotherapy Response Score with Multidrug Resistance 1 and CA125 ELIMination Rate Constant K in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
    Matsukuma K; Nishio S; Tasaki S; Park J; Nasu H; Yoshimitsu T; Tasaki K; Katsuda T; Terada A; Tsuda N; Sanada S; Ushijima K
    Kurume Med J; 2024 Jul; 70(1.2):29-37. PubMed ID: 38556270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy combined with interval cytoreductive surgery in ovarian cancer.
    Li X; Du X
    J BUON; 2019; 24(5):2035-2040. PubMed ID: 31786872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites.
    Liu EL; Mi RR; Wang DH; Wang LQ; Zhang YM; Chen WM
    Eur J Gynaecol Oncol; 2017; 38(2):209-213. PubMed ID: 29953782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The optimal time for surgery in women with serous ovarian cancer.
    Stewart JM; Tone AA; Jiang H; Bernardini MQ; Ferguson S; Laframboise S; Murphy KJ; Rosen B; May T
    Can J Surg; 2016 Aug; 59(4):223-32. PubMed ID: 27240134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study.
    Lee YJ; Lee JY; Cho MS; Nam EJ; Kim SW; Kim S; Kim YT
    J Gynecol Oncol; 2019 Jan; 30(1):e3. PubMed ID: 30479087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients.
    Kusunoki S; Terao Y; Hirayama T; Fujino K; Ujihira T; Ota T; Takeda S
    Taiwan J Obstet Gynecol; 2018 Oct; 57(5):650-653. PubMed ID: 30342644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis.
    Gammon DC; Dutton T; Piperdi B; Zybert J; Wolfe SH; Nguyen E; Sbat D; Pillarisetty VG; Sullivan M; Whalen GF
    Am J Health Syst Pharm; 2009 Jul; 66(13):1186-90. PubMed ID: 19535657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer.
    Cui HB; Ge HE; Bai XY; Zhang W; Zhang YY; Wang J; Li X; Xing LP; Guo SH; Wang ZY
    Exp Ther Med; 2014 May; 7(5):1083-1088. PubMed ID: 24940391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study.
    Zhu ZG; Tang R; Yan M; Chen J; Yang QM; Li C; Yao XX; Zhang J; Yin HR; Lin YZ
    Dig Surg; 2006; 23(1-2):93-102. PubMed ID: 16763374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical effect of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer].
    Zhu ZG; Tang R; Yan M; Chen J; Yang QM; Li S; Yao XX; Zhang J; Yin HR; Lin YZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jan; 9(1):26-30. PubMed ID: 16437366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.